Ritu Jakhar

Ritu Jakhar

Auto-generated profile, based on publicly available information

Ritu Jakhar

Centre for Bioinformatics, Maharshi Dayanand University, Rohtak, 124001, India

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
MDMehak Dangi
Mehak Dangi
AKAlka Khichi
Alka Khichi
RJRitu Jakhar
Ritu Jakhar
ACAnil K. Chhillar
Anil K. Chhillar
Background: The major concern of today's time is the developing resistance in the most of the clinically derived pathogenic micro-organisms for the available drugs through several mechanisms. So, there is an acute need to develop novel molecules with drug like properties that can be effective against the otherwise resistant micro-organisms. Methods: New drugs can be developed using several methods like structure based drug design, ligand based drug design or by developing analogues of the available drugs to improve their effect further. But the smartness is to opt for the techniques that involve lower expenditure, lower failure rates and faster discovery rates. Results: Analogue based drug design (ABDD) is one such technique that researchers worldwide are opting to develop new drug like molecules with comparatively lower market values.They start by first designing the analogues sharing structural and pharmacological similarities to the existing drugs. This method embark on scaffold structures of available drugs already approved by the clinical trials, but are left ineffective because of resistance developed by the pathogens. Conclusion: In this review we have stated some recent examples of anti-fungal and anti-bacterial (antimicrobial) drugs that were designed based on ABDD technique. Also we have tried to focus on the in silico tools and techniques that can contribute for the designing and computational screening of the analogues, so that these can be further taken for in vitro screening to validate their better biological activities against the pathogens with comparatively reduced rates of failure.

1 September 2026 in Current Computer-Aided Drug Design
Verified
Journal Article
Closed access
PDF file
DKDev Kumar
Dev Kumar
BHBhoomika
Bhoomika
AKAlka Khichi
Alka Khichi
RJRitu Jakhar
Ritu Jakhar
MDMehak Dangi
Mehak Dangi
Introduction: Tuberculosis (TB) is one of the most serious global health issues, with the increasing number of multidrug-resistant TB cases emphasizing the need for new therapeutic approaches. Phytochemicals, with their diverse structures and favorable safety profiles, are a largely unexplored area for anti-TB drug development. Methods: An ethnobotanical study and literature analysis identified 310 medicinal plants traditionally used to treat respiratory infections, which produced 4,087 phytochemicals. Their structures were obtained from PubChem or drawn using ChemDraw, and pharmacokinetic properties were analyzed using QikProp. Enoyl-acyl carrier protein reductase (InhA, PDB ID: 4TRO), an important enzyme involved in mycolic acid biosynthesis, was selected as the target protein. Molecular docking was performed using Glide, followed by MMGBSA calculations, and the best hits were validated by 300 ns molecular dynamics simulations using the GROMACS pipeline. Results: Binding affinities showed that four phytochemicals, namely Patuletin, skimmin, flavonol- 3-O-D-glycoside, and salicin, had significantly higher binding affinity scores (-10.06 to -8.82 kcal/mol) than first-line anti-TB drugs isoniazid (-6.35 kcal/mol) and pyrazinamide (-4.22 kcal/mol). Patuletin and skimmin had MM-GBSA binding affinity scores of -74.89 and -71.76 kcal/mol, respectively. MD simulations of the top 3 compounds and control showed that the protein-ligand complexes were stable, as indicated by the RMSD, RMSF, Radius of gyration, SASA, and HBONDS. Discussion: Patuletin and Skimmin demonstrated strong binding affinity and structural stability against the InhA enzyme (PDB: 4TRO), indicating their potential as promising lead compounds for anti-tuberculosis effects. Derived from ethnomedicinal plants, these phytochemicals not only target key mycobacterial pathways but may also offer hepatoprotective and immunomodulatory benefits. The findings support the exploration of plant-derived compounds as safer and effective alternatives or adjuncts to conventional anti-TB therapies. Conclusion: The combination of virtual screening, ADME studies, and MD simulations enabled the identification of phytochemicals with promising interactions toward InhA, an established anti-TB target. The findings are based solely on computational analysis and should be interpreted as preliminary evidence of target engagement rather than confirmed inhibitory activity or therapeutic efficacy. These natural products may serve as potential lead compounds for further anti-tubercular drug discovery, warranting subsequent biochemical, cellular, and in vivo validation to establish their inhibitory potential, safety, and pharmacological effectiveness.